📰 Nasdaq Elev News
Nasdaq Elev News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Nasdaq Elev. Real-time updates on events, politics, business and more.
December 19, 2023
Elevation Oncology, Inc. (NASDAQ:ELEV – Get Free Report) saw a significant decrease in short interest in November. As of November 30th, there was short interest totalling 593,500 shares, a decrease of 10.8% from the November 15th total of 665,100 shares. Approximately 1.8% of the company’s shares are short sold. Based on an average trading volume […]
December 19, 2023
Elevation Oncology, Inc. (NASDAQ:ELEV – Get Free Report) was the recipient of a large decline in short interest in the month of November. As of November 30th, there was short interest totalling 593,500 shares, a decline of 10.8% from the November 15th total of 665,100 shares. Based on an average daily trading volume, of 218,500 […]
December 10, 2023
Caxton Corp decreased its holdings in shares of Elevation Oncology, Inc. (NASDAQ:ELEV – Free Report) by 68.2% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 21,725 shares of the company’s stock after selling 46,599 shares during the period. Elevation Oncology makes up approximately 0.1% of […]
November 10, 2023
Wedbush reiterated their outperform rating on shares of Elevation Oncology (NASDAQ:ELEV – Free Report) in a research report report published on Monday morning, Benzinga reports. They currently have a $5.00 price objective on the stock. Wedbush also issued estimates for Elevation Oncology’s Q4 2023 earnings at ($0.26) EPS, FY2023 earnings at ($1.21) EPS, Q1 2024 […]
October 3, 2023
HC Wainwright initiated coverage on shares of Elevation Oncology (NASDAQ:ELEV – Free Report) in a research report sent to investors on Friday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $1.50 target price on the stock. Elevation Oncology Stock Up 1.9 % ELEV opened at $0.68 on Friday. The firm has […]
September 12, 2023
Elevation Oncology (NASDAQ:ELEV – Get Free Report) and Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends and valuation. Volatility & Risk Elevation Oncology has […]
August 1, 2023
Elevation Oncology, Inc. (NASDAQ:ELEV – Get Free Report) was the target of a significant drop in short interest in July. As of July 15th, there was short interest totalling 1,320,000 shares, a drop of 11.4% from the June 30th total of 1,490,000 shares. Based on an average daily volume of 1,940,000 shares, the short-interest ratio […]
June 5, 2023
BML Capital Management LLC bought a new position in shares of Elevation Oncology, Inc. (NASDAQ:ELEV – Get Rating) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 39,963 shares of the company’s stock, valued at approximately $38,000. Elevation Oncology accounts for 0.0% […]
June 3, 2023
SVB Securities upgraded shares of Elevation Oncology (NASDAQ:ELEV – Get Rating) from a market perform rating to an outperform rating in a report issued on Tuesday, The Fly reports. SVB Securities currently has $8.00 target price on the stock, up from their previous target price of $5.00. Separately, Wedbush reiterated an outperform rating and set […]
June 2, 2023
SVB Leerink upgraded shares of Elevation Oncology (NASDAQ:ELEV – Get Rating) from a market perform rating to an outperform rating in a research report report published on Tuesday morning, PriceTargets.com reports. A number of other analysts have also recently issued reports on ELEV. Wedbush restated an outperform rating and set a $4.00 price objective on […]